Sars-Cov2 Pneumonia in Mexico
DOI:
https://doi.org/10.14738/bjhmr.115.17658Keywords:
Pneumonia, Atypical, SARS-COV2, Covid 19, Hypoxia, C-reactive proteinAbstract
Introduction: pneumonia is a very common pathology and, in some countries, it is a fatal in-hospital complication. However, at the end of November 2019, the first cases of acute respiratory syndrome were reported in people in the city of Wuhan, China. It was initially called atypical pneumonia. Objective: to report the experience of SARS-COV2 pneumonia at the "El Vergel" Zone Military Hospital. Method: this is a retrospective, longitudinal, cross-sectional, observational and descriptive study, in a period of time carried out in a second-level medical care hospital. Results: 220 patients with SARS-COV2 pneumonia disease are reported. Of which 145 male patients are 66% and 75 female patients representing 34%. Confirmation of the diagnosis for covid 19 was carried out by nasopharyngeal PCR for Sars-cov-2. Most of the cases are severe and present hypoxia on admission, classifying the covid 19 disease as mild (3.6%), moderate (15.9%) and severe (80.4%). Conclusions: atypical pneumonia due to SARS-COV2 is a disease with a high level of virulence and/or pathogenicity in terms of clinical progression and aggressiveness, its mortality is overwhelming, hence the importance of presenting this research.
References
Del Río C., Malani P.M. COVID-19: nuevos conocimientos sobre una epidemia que cambia rápidamente. JAMA 2020; 323: 1339 – 40. Doi: 10.1001/jama.2020.3072
OMS.Panel de control de la OMS sobre el coronavirus (covid 19) Disponible en: https://data.who.int/dashboards/covid19/cases?n=c 105
Ueda A., Nohara K., Obara M., Watanabe S. Analysis of anticholinergic drugs associated with aspiration pneumonia using the Japanese adverse drug event report database: Supplementary insights from a scoping review. Respir Investig. 2024; 62(6):1044-1050.
Ochoa H., E., Galindo F., A., & Sifuentes O., J. 2020) Nuevo coronavirus (SARS-CoV-2). Incmnsz.mx. Revisado el 12/09/20244 en http://www.incmnsz.mx/opencms/Coronavirus.html.
OMS, Organización Mundial de la Salud. Neumonía de causa desconocida – China, 05 Enero 2020. Revisado el 12/09/24 en https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/es/accessed.
Chan J.F.W., Kok K.H., Zhu Z., et al. Genomic Characterization of the 2019 Human Pathogenic Novel Coronavirus Isolated from a Patient with Atypical Pneumonia After Visiting Wuhan. Microbes and emerging infections. 2021: 9 (1), 221-236.
Ferrando, C., Mellado-Artigas, R., Gea, A., y cols. Características de los pacientes, evolución clínica y factores asociados a la mortalidad en UCI en pacientes críticos infectados por SARS-CoV-2 en España: estudio prospectivo, de cohortes y multicéntrico. Características, evolución clínica y factores asociados a la mortalidad en UCI de los pacientes críticos infectados por SARS-CoV-2 en España: estudio prospectivo, de cohorte y multicéntrico. Revista española de anestesiología y reanimación. 2020; 67(8), 425–437.
Barcena M., Oostergetel G.T., Bartelink W., et al. Cryo-electron tomography of mouse hepatitis virus: information on the structure of the coronavirion. Proc Natl Acad Sci USA 2009: 106:582–587.
Fehr A.R., Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier H., Bickerton E., Britton P. (eds) Coronaviruses. Methods in Molecular Biology, 2015: 1282. Humana Press, New York, NY.
Oksanen L.M., Geneid A., Sanmark E., Vuorinen V. Superspreading of SARS-CoV-2 at a choir rehearsal in Finland-A computational fluid dynamics view on aerosol transmission and patient interviews. PLoS One. 2024; 19(9): e0302250.
Palacios-Cruz M., Santos E., M.A. Velázquez-Cervantes, y cols. COVID-19, una emergencia de salud pública mundial. Revista Clínica Española. 2021; 1:55-61.
Widagdo, W., Sooksawasdi N.A. S., Hundie, G.B., et al. BL host determinants of MERS-CoV transmission and pathogenesis. Virus. 2019: 11; 280.
Jones B.S., DeWitt M.E., Wenner J.J., Sanders J.W. Lyme Disease Under-Ascertainment During the COVID-19 Pandemic in the United States: Retrospective Study. JMIR Public Health Surveill. 2024; 10: e56571.
Suárez V., Suarez-Quezada M., Oros-Ruiz S., y cols. Epidemiología de COVID-19 en México: del 27 de febrero al 30 de abril de 2020. Revista Clínica Española. 2020; (220)8: 463-471.
Mancilla-Galindo J., García-Méndez J.Ó., Márquez-Sánchez J., et al. All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study. EXCLI J. 2021; (4) 20:199-222.
Informe Técnico Diario COVID-19 MÉXICO.04.02.2021 (datos consolidados a las 19:00 horas del 04.02.2021) [Internet]. Gobierno de México. Secretaría de Salud. Subsecretaría de Prevención y Promoción de la Salud; 2021 abr. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/614182/Comunicado_Tecnico_Diario_COVID-19_2021.02.04.pdf. (2024). Sars-Cov2 Pneumonia in Mexico. British Journal of Healthcare and Medical Research, Vol - 11(5). 98-108.
Moghnieh R., Haddad W., Jbeily N., et al. Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization. PLoS One. 2024; 19(9): e0306457.
Dirección General de Epidemiología, Secretaría de Salud. Lineamiento estandarizado para la vigilancia epidemiológica y por laboratorio de la enfermedad respiratoria viral. DGE, SSA; México: agosto de 2020. Revisado el 12/09/24. Dispoible en: https://coronavirus.gob.mx/wpcontent/uploads/2020/09/Lineamiento_VE_y_Lab_Enf_Viral_Ago-2020.pdf.
Elbarazi I., Al-Balushi J., Al-Dhaheri A., et al. Public Health Ambassadors: A Novel Participatory Community Health Awareness Program in Abu Dhabi. Inquiry. 2024; 61:469580241241268. doi: 10.1177/00469580241241268.
Rahimi-Ardabili H., Magrabi F., Sanderson B., et al. A qualitative analysis of health service problems and the strategies used to manage them in the COVID-19 pandemic: exploiting generic and context-specific approaches. BMC Health Serv Res. 2024; 24(1):1067.
Liu Y., Wang W., Wong W.K., Zhu W. Effectiveness of non-pharmaceutical interventions for COVID-19 in USA. Sci Rep. 2024; 14(1):21387. doi: 10.1038/s41598-024-71984-1.
Kiliç H., Argüder E., Civak M., et al. Is using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality? Tuberk Toraks. 2024. 72(3):219-228.
Bell J.A., Carslake D., Hughes A., et al. Adiposity and mortality among intensive care patients with COVID-19 and non-COVID-19 respiratory conditions: a cross-context comparison study in the UK. BMC Med. 2024;
Ruiz R. Asma como factor asociado a disminución de la mortalidad en población mexicana con COVID-19 [Asthma as a Protective Factor Against Mortality in Mexican Population with COVID-19]. Rev Med Chil. 2023; 151(11):1437-1445.
Zeladita-Huaman J.A., Aparco J.P., Franco-Chalco E., et al. Emotional Impact of COVID-19 and Emotional Eating and the Risk of Alcohol Use Disorder in Peruvian Healthcare Students. Nutrients. 2024;
Mmari K., Harper K., Kawatachi J., et al. The Association between Federal Nutrition Assistance Programs and Adolescent Food Security during the COVID-19 Pandemic: Evidence from Baltimore, Maryland. Nutrients. 2024; 16(17):2876.
Santana-de Anda K., Torres-Ruiz J., Mejía-Domínguez N.R., et al. Novel Clinical, Immunological, and Metabolic Features Associated with Persistent Post-Acute COVID-19 Syndrome. Int J Mol Sci. 2024;
Bustin S.A. RT-qPCR Testing and Performance Metrics in the COVID-19 Era. Int J Mol Sci. 2024; 25(17):9326. doi: 10.3390/ijms25179326.
LDrzymała A. The Functions of SARS-CoV-2 Receptors in Diabetes-Related Severe COVID-19. Int J Mol Sci. 2024; 25(17):9635. doi: 10.3390/ijms25179635. lanos-Jiménez L.,
Lu C.K., Lung J., Shu L.H., et al. The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants. Int J Mol Sci. 2024; 25(17):9498. doi: 10.3390/ijms25179498.
Hobbs K.J., Bayless R., Sheats M.K. A Comparative Review of Cytokines and Cytokine Targeting in Sepsis: From Humans to Horses. Cells. 2024; 13(17):1489. 107
Alvarez-Alvarez B., Fonseca-Aizpuru E., et al. CSACOVID-IISFJD Team. Cyclosporin A as an Add-On Therapy to a Corticosteroid-Based Background Treatment in Patients with COVID-19: A Multicenter, Randomized Clinical Trial. J Clin Med. 2024; 13(17):5242.
Karrer S., Unger P., Gruber M., et al. In Vitro Safety Study on the Use of Cold Atmospheric Plasma in the Upper Respiratory Tract. Cells. 2024; 13(17):1411. doi: 10.3390/cells13171411.
Pérez C., González-Agüero M.., Bravo P. Percepciones y experiencias de usuarios que recibieron cuidados ambulatorios de COVID-19 en Santiago de Chile [Perceptions and experiences of users who received outpatient COVID-19 care in Santiago, Chile]. Rev Med Chil. 2024; 152(1):61-68.
Camp D., Caputo M., Echevarria F.M., et al. Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19. BMC Infect Dis. 2024; 24(1):963.
Zhao H., Meng W., Lv X., et al. Nebulized inhalation of plasma-activated water in the treatment of progressive moderate COVID-19 patients with antiviral treatment failure: a randomized controlled pilot trial. BMC Infect Dis. 2024; 24(1):960.
Levey A.O., Chen G.H., Ngyuen A., et al. The Effectiveness and Safety of Stellate Ganglion Block in the Treatment of Symptoms from Long COVID-19: A Pilot Study. Psychopharmacol Bull. 2024; 54(4):8-17.
Lother S.A., Tennenhouse L., Rabbani R., et al. The association of antiplatelet agents with mortality among patients with non-COVID-19 community-acquired pneumonia: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2024; 8(5):102526.
Banerjee S., Mukherjee S., Mohsin Kazi., et al. Anti- COVID-19 drug discovery by flavonoid derivatives: an extensive computational drug design approach. Cell Mol Biol (Noisy-le-grand). 2024; 70(8):39-49.
Paull J.R.A., Luscombe C.A., Seta A., et al. Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epithelium. Sci Rep. 2024; 14(1):21259.
Song Y., Lu J., Qin P., et al. Interferon-I modulation and natural products: Unraveling mechanisms and therapeutic potential in severe COVID-19. Cytokine Growth Factor Rev. 2024: S1359-6101(24)00066-2. Doi: 10.1016/j.cytogfr.2024.08.005.
Zhang Y., Li Y., Zhong D., et al. Clinical practice guidelines and expert consensus statements on rehabilitation for patients with COVID-19: a systematic review. BMJ Open. 2024; 14(9): e086301.
Lee J.H., Jeon H., Lötvall J., Cho B.S. Therapeutic potential of mesenchymal stem cell-derived extracellular vesicles in SARS-CoV-2 and H1N1 influenza-induced acute lung injury. J Extracell Vesicles. 2024; 13(9): e12495.
Mohammadinia L., Saadatmand V., Khaledi Sardashti H., et al. Hospital response challenges and strategies during COVID-19 pandemic: a qualitative study. Front Public Health. 2023; (30) 11:1167411.
Karakoc H.N., Aydin M., Ozcan S.N., et al. To prescribe or not: a two-center retrospective observational study of antibiotics usage and outcomes of COVID-19 in Turkey. Sci Rep. 2024; 14(1):21031.
Městecký J., Raška M. COVID-19: to vaccinate or not to vaccinate - that is the question. Cas Lek Cesk. 2024;163(4):131-136.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Bertha Zenaida Acevedo Martínez, Óscar Escalante Piña, Javier López Jarquin, Olaf Alejandro López Arias, Bruno París Rómero Ángeles, Marta Estela Miranda Rendón, Karla Ixchel Contreras Solis, Carolina Jimarez Franco, Morelos Adolfo García Sánchez

This work is licensed under a Creative Commons Attribution 4.0 International License.